The complex between urokinase-type plasminogen activator (uPA) and tis type-1 inhibitor (PAI-1) independently predicts response to first-line endocrine therapy in advanced breast cancer

Thrombosis and Haemostasis

Volumn 91, Issue 3, 2004, Pages 514-521

  Manders, Peggy ^a   Tjan Heijnen, Vivianne C G ^a   Span, Paul N ^a   Grebenchtchikov, Nicolai ^a   Geurts Moespot, Anneke J ^a   van Tienoven, Doorléne T H ^a   Beex, Louk V A M ^a   Sweep, Fred C G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Advanced breast cancer; Plasminogen activator inhibitor type 1; Predictive; uPA:PAI 1 complex; Urokinase type plasminogen activator

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN; UROKINASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER TISSUE; COMPLEX FORMATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PLASMINOGEN ACTIVATION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; STATISTICAL ANALYSIS; SURVIVAL TIME; TREATMENT INDICATION;

EID: 1642288409     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-07-0467     Document Type: Article

References (23)

1. Danø K, Andreasen PA, Grøndahl-Hansen J, et al.. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266.
2. Andreasen PA, Kjoller L, Christensen L, et al.. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 1997; 72: 1-22.
3. Schmitt M, Harbeck N, Thomssen C, et al.. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997; 78: 285-96.
4. Duffy MJ, Maguire TM, McDermott EW, et al.. Urokinase plasminogen activator: A prognostic marker in multiple types of cancer. J Surg Oncol 1999; 71: 130-5.
5. Jänicke F, Prechtl A, Thomssen C, et al.. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst 2001; 93: 913-20.
6. Look MP, Putten WLJ van, Duffy MJ, et al.. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst 2002; 94: 116-28.
7. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002; 20: 1000-7.
8. Harbeck N, Kates RE, Look MP, et al.. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 2002; 62: 4617-22.
9. Foekens JA, Look MP, Peters HA, et al.. Urokinase-type plasminogen activator and its inhibitor PAI-1: Predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst 1995; 87: 751-6.
10. Grebenschikov N, Sweep F, Geurts A, et al.. ELISA for complexes of urokinase-type and tissue-type plasminogen activators with their type-1 inhibitor (uPA-PAI-1 and tPA-PAI-1). Int J Cancer 1999; 81: 598-606.
11. Pedersen AN, Høyer-Hansen G, Brünner N, et al.. The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Immunol Methods 1997; 203: 55-65.
12. Pedersen AN, Christensen IJ, Stephens RW, et al.. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 2000; 60: 6927-34.
13. Sten-Linder M, Seddighzadeh M, Engel G, et al.. Prognostic importance of the uPA/PAI-1 complex in breast cancer. Anticancer Res 2001; 21: 2861-6.
14. Koenders AJM, Geurts-Moespot A, Zollingen S, et al.. Progesterone and estradiol receptors in DMBA-induced mammary tumors before and after ovariectomy and after subsequent estradiol administration. In: Progesterone receptors in normal and neoplastic tissues (Progress in Cancer and therapy). McGuire W, Raynaud J, Baulieu E. New York, NY, Raven Press 1977; 71-84.
15. Lowry OH, Rosebrough NJ, Farr AL, et al.. Protein measurements with the folin reagent. J Biol Chem 1951; 193: 265-75.
16. Grebenschikov N, Geurts-Moespot A, Witte H de, et al.. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type I (PAI-1) in breast tumor cytosols. Int J Biol Markers 1997; 12: 6-14.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J 1958; 53: 457-81.
18. Xing RH, Mazar A, Henkin J, et al.. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997; 57: 3585-93.
19. Abidi SMA, Howard EW, Dmytryk JJ, et al.. The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells. Clin Exp Metastasis 1998; 16: 235-41.
20. Levenson AS, Svoboda KM, Kwaan HC, et al.. Agonist activity of anti-estrogen-receptor complexes to regulate urokinase activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) endogenous gene expression in breast cancer cells. Cancer Letters 1998; 125: 215-20.
21. Webb DJ, Thomas KS, Gonias SL. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth. J Cell Biol 2001; 152: 741-52.
22. Knight WA 3rd, Osborne CK, McGuire WL. Hormone receptors in primary and advanced breast cancer. J Clin Endocrinol Metab 1980; 9: 361-8.
23. Osborne CK, Yochmowitz MG, Knight WA 3rd, et al.. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 1980; 46: 2884-8.